OraLiva, Inc. Announces Launch of Clinically Validated, AI-Powered Oral Cancer Test
OraLiva, Inc. announced the commercial launch of its AI-powered oral cancer and oral lesion test, a powerful non-invasive test designed to empower dentists and clinicians to detect and monitor lesions of concern earlier, when outcomes are most favorable. OraLiva has partnered with Delta Dental Plan of Michigan, Inc., Delta Dental Plan of Ohio, Inc., Delta Dental Plan of Indiana, Inc. (collectively “DDMI”), and Delta Dental of North Carolina (“DDNC”) 1 on the launch to make the test available as a covered procedure. The test, a “thermometer for cancer,” is intended for use by dentists, periodontists, oral and maxillofacial surgeons, and ENTs. Samples are collected quickly with a simple brush of the lesion during a routine clinical visit by hygienists or dentists. OraLiva’s test can also be used in surveillance testing of high-risk or recurrent patients and similarly be collected by nurses, trained assistants, or specialists. Built on one of the largest NIH-...
